Foley Hoag LLP represented Ginkgo Bioworks on the agreement. Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug...
You must be a Standard 1 Year member to access this content.
Foley Hoag represented Ginkgo Bioworks on the deal. Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading platform for cell programming and biosecurity, announced its acquisition of StrideBio’s adeno-associated...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised Daewoong Pharmaceutical on the deal. South Korea’s Daewoong Pharmaceutical (“Daewoong”) secured an exclusive licensing agreement with CS Pharmaceuticals, a UK based multinational company focused...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised H.I.G. BioHealth Partners and Accelmed Partners on the deal. H.I.G. BioHealth Partners and Accelmed Partners acted as new investors and co-leads in the...
You must be a Standard 1 Year member to access this content.
